PATRICIA ASPICHUETA CELAA-rekin lankidetzan egindako argitalpenak (31)

2023

  1. Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS−/− mouse model of metabolic nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

    NMR in Biomedicine, Vol. 36, Núm. 8

  2. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  3. In Vivo Hepatic Triglyceride Secretion Rate in Antisense Oligonucleotide (ASO)-Treated Mice

    Methods in molecular biology (Clifton, N.J.), Vol. 2675, pp. 15-26

  4. In Vivo Tissue Lipid Uptake in Antisense Oligonucleotide (ASO)-Treated Mice

    Methods in molecular biology (Clifton, N.J.), Vol. 2675, pp. 1-13

2022

  1. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

    Hepatology, Vol. 76, Núm. 6, pp. 1617-1633

  2. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

  3. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  4. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

2021

  1. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  2. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  3. The L-α-Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis

    Hepatology, Vol. 73, Núm. 2, pp. 606-624

2020

  1. Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease

    Aging Cell, Vol. 19, Núm. 8

  2. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

    Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10

2019

  1. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)

    Revista Española de Enfermedades Digestivas, Vol. 111, Núm. 4, pp. 264-269

  2. p107 Deficiency Increases Energy Expenditure by Inducing Brown-Fat Thermogenesis and Browning of White Adipose Tissue

    Molecular Nutrition and Food Research, Vol. 63, Núm. 2

2018

  1. Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice

    Scientific Reports, Vol. 8, Núm. 1

  2. Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

    Molecular Metabolism, Vol. 8, pp. 132-143

2017

  1. Corrigendum: Hepatic p63 regulates steatosis via IKKβ/ER stress

    Nature communications

  2. Hepatic p63 regulates steatosis via IKKβ/ER stress

    Nature Communications, Vol. 8

  3. Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance

    Cell Metabolism, Vol. 26, Núm. 1, pp. 212-229.e12